dr. eggermont on the rationale for evaluating adjuvant pembrolizumab in advanced melanoma
Published 3 years ago • 132 plays • Length 1:39Download video MP4
Download video MP3
Similar videos
-
1:34
dr. eggermont on responses to adjuvant pembrolizumab in stage iii melanoma subtypes
-
1:53
dr. eggermont discusses impact of pembrolizumab in melanoma
-
2:40
dr. eggermont on the impact of adjuvant anti–pd-1 agents in melanoma
-
40:18
evolution of melanoma therapies from advanced to (neo)adjuvant (alexander eggermont)
-
1:22
dr. weber on adjuvant pembrolizumab in melanoma
-
3:20
considerations surrounding adjuvant therapy in melanoma
-
10:36
results of keynote-054; melanoma patients treated with pembrolizumab
-
2:57
identifying patients for neoadjuvant melanoma therapy
-
5:54
keynote-716: adjuvant therapy with pembrolizumab for patients with high-risk stage ii melanoma
-
1:36
results from keynote-716: adjuvant therapy with pembrolizumab in high-risk stage ii melanoma
-
1:15
dr. weber on nivolumab in the adjuvant setting for melanoma
-
5:15
adjuvant therapy for locally advanced melanoma
-
47:59
the future of melanoma: what to anticipate in 2023 with neoadjuvant and adjuvant pembrolizumab
-
4:14
adjuvant therapy for melanoma: novel treatment options
-
1:43
dr. moyers on real-world data with adjuvant immunotherapy in melanoma
-
9:40
reducing recurrence of advanced melanoma with pembrolizumab
-
9:35
adjuvant treatment selection in high-risk melanoma
-
6:52
expert report on novel data in (neo)adjuvant treatment of melanoma from asco 2022